“This grant will expand the growing body of evidence of Talotrexin’s efficacy in combination with various novel cytotoxic and targeted therapeutic agents in arresting tumor growth,” said Dr Mark Ahn, president and chief executive officer.
“Our grant applications continue to score highly with the NIH’s external panel of oncology experts who are impressed with Talotrexin’s potential therapeutic benefits, as well as with our drug development team’s ability to move drug candidates from the laboratory to the clinic on a timely basis,” added Dr Ahn.
Talotrexin is being developed for a wide range of tumors including NSCLC (non-small cell lung cancer), ALL (acute lymphocytic leukemia), cervical, endometrial, and ovarian cancers. In pre-clinical tests, Talotrexin has been shown to enter into cells up to 10-times more efficiently than currently available treatments in the same class.
Hana Biosciences is San Francisco-based biopharmaceutical company that acquires, develops, and commercializes innovative products to advance cancer care.